Bristol-Myers Squibb Consolidates its Candiac Clinical Supply Operations
CANDIAC (Quebec), CANADA – (February 26, 2007) – Bristol-Myers Squibb Canada announced today the consolidation of its Clinical Supply Operations (CSO) and related functions located in Candiac into its newly expanded New Brunswick, New Jersey facility.
This decision was made after careful consideration with the objectives of improving Bristol-Myers Squibb (BMS) performance, delivering pipeline value and ensuring the Company can effectively discover, develop, manufacture and sell medicines that extend and enhance human life.
The CSO and related functions represented seventy-five percent of all Candiac site positions. With the consolidation of these operations, BMS had to consider the cost effectiveness of maintaining the Candiac facility, and made the decision to close it.
Approximately 115 employees are affected by this decision, and a number of them will be offered opportunities to transfer to New Brunswick, New Jersey and other BMS sites located in the United States. Others will be offered severance pay and outplacement assistance. BMS is highly committed to making this transition as easy as possible for employees and their families.
About Bristol-Myers Squibb Canada
Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global pharmaceutical and related health care products company whose mission is to extend and enhance human life. Bristol-Myers Squibb Company is a leading provider of medicines to fight cancer, cardiovascular and metabolic disorders, infectious diseases (including HIV/AIDS), nervous system diseases and serious mental illness. Bristol-Myers Squibb Company is listed on the New York Stock Exchange under the BMY symbol (NYSE:BMY). Bristol-Myers Squibb Canada's operations are headquartered in Montréal, Québec.
For further information, please contact:
Senior Manager of Public Affairs
Bristol-Myers Squibb Canada